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Abstract
Adaptations to the gold standard randomised controlled trial (RCT) have been introduced to decrease trial costs
and avoid high sample sizes. To facilitate development of precision medicine algorithms that aim to optimise
treatment allocation for individual patients, we propose a new RCT adaptation termed the nested-precision RCT
(npRCT). The npRCT combines a traditional RCT (intervention A versus B) with a precision RCT (stratified versus
randomised allocation to A or B). This combination allows online development of a precision algorithm, thus
providing an integrated platform for algorithm development and its testing. Moreover, as both the traditional and
the precision RCT include participants randomised to interventions of interest, data from these participants can be
jointly analysed to determine the comparative effectiveness of intervention A versus B, thus increasing statistical
power. We quantify savings of the npRCT compared to two independent RCTs by highlighting sample size
requirements for different target effect sizes and by introducing an open-source power calculation app. We
describe important practical considerations such as blinding issues and potential biases that need to be considered
when designing an npRCT. We also highlight limitations and research contexts that are less suited for an npRCT. In
conclusion, we introduce the npRCT as a novel precision medicine trial design strategy which may provide one
opportunity to efficiently combine traditional and precision RCTs.
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Background
In the wake of precision medicine, adaptations of the
“gold standard” randomised controlled trial (RCT) have
been introduced to accelerate the identification of perso-
nalised treatments, decrease trial costs, and avoid un-
necessarily high sample sizes. These include adaptation
studies such as the platform, linked Bayesian adaptive
randomisation, or leapfrog design that utilise early stop-
ping rules or (biomarker-dependent) mid-trial changes
in allocation ratio [1–4]. We propose a new RCT adap-
tation that could facilitate the move towards precision
medicine, which aspires to give personalised treatment
suggestions based on participant characteristics or
pathological markers.
The problem of retrospective precision algorithm
development
To move towards precision medicine, researchers need
to identify participant characteristics or pathological
markers that are prescriptive, meaning they are inform-
ative on whether any individual participant benefits
more from one treatment over another. As prescriptive
markers for different interventions are often not known,
current research efforts often revolve around re-
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analysing existing RCT data to identify pre-treatment
prescriptive variables and define precision algorithms.
A promising example for precision algorithm develop-
ment in psychiatry is the Personalised Advantage Index
(PAI) [5]. The PAI was developed based on a combination
of prescriptive pre-treatment variables and provides a
quantitative preference score on whether intervention A
or intervention B is likely to be the optimal treatment for
any individual participant. While approaches such as the
PAI are fruitful for the development of new stratification
rules, previous efforts have largely been restricted to algo-
rithm development using existing RCT data. If precision
algorithms were to find their way into clinical care, how-
ever, they would ideally require prospective testing similar
to how interventions are evaluated more generally; that is,
while interventions need to show empirical superiority
over placebo or current gold standard treatments, preci-
sion algorithms should exhibit empirical superiority over
random allocation to interventions.
To address the problematic predominance of retro-
spective precision algorithm development and lack of
prospective evaluation, we propose what we term
nested-precision RCT (npRCT), which allows for inte-
grated precision algorithm development and evaluation.
Introducing the npRCT
Design and statistical power
As depicted in Fig. 1a, the npRCT combines a trad-
itional RCT, comparing intervention A versus B, with a
precision RCT, comparing stratification to intervention
A or B versus randomisation to A or B.
This RCT combination has a twofold purpose. First
and as noted above, combining these two RCT types can
provide an integrated platform that allows for sequential
development and testing of a precision algorithm. Spe-
cifically, researchers can analyse collected data during
the traditional RCT to see if any strong prescriptive var-
iables are present that could guide treatment choice. For
example, identification of pre-treatment prescriptive var-
iables can be conducted using the PAI approach, which
looks for treatment-moderating variables using different
regression-based and machine learning techniques [6].
Ideally, any of such online analyses of traditional RCT
data should be conducted by an independent trial collab-
orator/statistician that is not involved in day-to-day
recruitment or treatment procedures, so as to prevent
potential researcher biases. If prescriptive variables are
identified that could optimise intervention allocation de-
cisions, researchers can move on to the precision RCT
stage, in which the algorithm is prospectively evaluated
against random intervention allocation.
The second purpose of the npRCT is to offer a design
that can save trial costs as compared to running trad-
itional and precision RCTs independently. As both the
traditional and the precision RCT include participants
randomised to interventions of interest, the traditional
RCT can be understood as nested within the combined
npRCT design. As such, all individuals randomised to
interventions of interest can be jointly analysed to deter-
mine the comparative intervention effectiveness of inter-
ventions A and B. This nesting increases statistical
power by reducing the sample size of the traditional
RCT by 1/2 times the sample size of the precision RCT.
Practical considerations
We want to highlight three major practical consider-
ations that should be made when setting up an npRCT.
First, researchers should consider effect size and allo-
cation ratio criteria a priori that determine if it is sens-
ible to move on to the precision RCT stage or to
maintain the traditional RCT. In terms of effect sizes, re-
searchers need to specify minimum effect size benefits
of the precision algorithm. If an effective algorithm can
be identified based on this criterion, researchers can
move on to the precision RCT stage. If an effective algo-
rithm cannot be identified based on this criterion, re-
searchers could maintain the traditional RCT design to
focus on the comparative intervention effectiveness
evaluation. Similarly, researchers should carefully con-
sider how overall intervention main effects are weighed
against treatment-moderating effects: Take a hypothet-
ical example where intervention A is more effective than
intervention B overall (i.e. a significant intervention main
effect is present). Under this scenario, the algorithm may
allocate a majority of participants to intervention A and
only few participants to intervention B. If effectiveness
differences are too large, a precision algorithm will lose
its economic value as a precision medicine tool as it
would make more sense to allocate all participants to
intervention A irrespective of any prescriptive variables.
Second, researchers need to carefully consider poten-
tial blinding issues and biases arising from the npRCT,
which are particularly likely if interventions cannot be
concealed (e.g. through use of matched drug capsules).
For example, researchers might learn how the precision
algorithm allocates participants to interventions, which
could lead to potential experimenter biases. Experi-
menter and expectation biases may also change from
traditional to precision RCT stages. For example, partici-
pants might have a clear expectation that intervention A
works best for them, so may assume (if allocated to
intervention B) in the precision RCT stage that they
were not assigned by the precision algorithm. To avoid
expectation biases at the stratification stage, the aim
should be that all individuals involved in the trial (i.e.
participants, clinicians, and the research team) are
blinded, so that knowledge about allocation group will
not affect trial results.
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Third, it will be important to set up a timeline that
leaves sufficient time for online precision algorithm
development. It is sensible to start precision algorithm
development relatively late in the traditional RCT stage,
so as to maximise sample sizes used for algorithm iden-
tification. However, the benefit of maximising sample
sizes for algorithm identification should be weighed
against practical time requirements to conduct analyses,
especially if recruitment rate is high, to avoid potential
delays between traditional and precision RCTs at the
point of stratification.
Power calculation app
We have developed a free, open-source power calcu-
lation app for the npRCT that can be accessed via
https://nprct.shinyapps.io/nprct/. This app includes
power calculation strategies for (i) comparison of two
groups on a continuous outcome (based on two-
sample independent t tests), (ii) comparison of three
or more groups on a continuous outcome (based on
analysis of variance or ANOVA), and (iii) comparison
of two or more groups on a binary or categorical out-
come (based on χ2 tests).
Fig. 1 a The npRCT design. b Sample size savings of the npRCT compared to two independent RCTs is described for an example comparison of
two interventions on a continuous outcome and with varying effect sizes (as Cohen's d)
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This power calculation app shows savings with this de-
sign (in terms of participants per group) compared to
running the traditional and the precision RCT independ-
ently (see Fig. 1b). The power calculation app also pro-
vides the transition point from traditional to precision
RCT (cf. point of stratification); that is, the point of re-
cruitment at which one needs to change towards the
precision RCT design. Considering a continuous
outcome and comparison of two interventions, for
frequently reported small, medium, and large effect sizes,
the npRCT would require 196 (Cohen’s d = 0.2), 32 (d =
0.5), and 13 (d = 0.8) participants fewer per group com-
pared to two independent RCTs (assuming α = 0.05 and
power = 0.8). These statistics emphasise recruitment sav-
ings gained by combining/nesting RCTs under the
npRCT design.
In the power calculation app, we provide explanations
on further practical and ethical considerations. We also
provide a walk-through research example for the
npRCT. Source code of the npRCT app and power com-
putation functions are freely available via github under
https://github.molgen.mpg.de/mpip/npRCT.app, which
we encourage researchers to use and adapt for more
complex npRCT design setups (e.g. with traditional RCT
allocation ratios deviating from 1:1 allocation).
Advantages and limitations of the npRCT
We have proposed the npRCT as a strategy to integrate
precision algorithm development and testing of stratified
versus randomised allocation in a unified design and
outlined potential advantages of this design in terms of
participant savings. Despite these advantages, there are
several limitations of the npRCT that researchers need
to consider when deciding between clinical trial designs.
First, the npRCT does not allow answering of all re-
search questions relevant for precision medicine. For in-
stance, the precision RCT stage may enable investigators
to obtain a “theoretical” estimate of precision algorithm
effectiveness compared to random treatment allocation
assuming that the biases mentioned under the Practical
considerations section are minimised. In clinical prac-
tice, however, stratification algorithms may not be used
as absolute decision rules to select between treatments.
Instead, algorithmic decisions may be used as support
decision-making tools to guide clinicians’ and patients’
choices, so patients and clinicians could opt to ignore
the algorithmic recommendation as well. To obtain a
“practical” estimate of precision algorithm effectiveness
as a support decision-making tool would thus instead re-
quire an evaluation of randomised treatment allocation
versus algorithmic treatment recommendation, which
may not be a suitable research question for the npRCT
due to unique blinding and bias considerations.
Second, the assumption of ethical favourability of the
npRCT needs to be assessed individually for each re-
search context. For instance, recent simulation work on
precision algorithm development for major depression
has suggested that precision algorithm development it-
self requires very large sample sizes for a range of plaus-
ible algorithmic effect sizes reported in the literature [7].
In this report, the authors have even suggested that algo-
rithm development might realistically benefit from de-
velopment in non-randomised study settings, only to be
evaluated in a randomised trial subsequently. If npRCT
power calculation proves unrealistic for a specific re-
search context, we recommend the use of alternative
trial designs including separate algorithm development
and testing.
Conclusion
We describe the npRCT, which combines two RCTs ad-
dressing research questions on (i) comparative interven-
tion effectiveness (intervention A versus B) and (ii)
precision treatment allocation (stratified allocation ver-
sus randomised allocation to A or B). Combining these
two designs allows integrated precision algorithm devel-
opment and testing. It also increases statistical power,
which can be quantified using our free, open-source
power computation app. Based on the resulting partici-
pant savings, the npRCT may be ethically and economic-
ally favourable to conducting two RCTs independently
for certain research contexts. As such, we hope the
npRCT may constitute one means of fostering prospect-
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